老虎油有优的个人主页 - 老虎社区

老虎油有优

暂无个人介绍

IP属地：广东

4关注

0粉丝

0主题

0勋章

老虎油有优

03-25

这篇文章不错，转发给大家看看

@资本要闻:美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学的保罗·威廉·拉登森教授莅临中肿超声科交流甲状腺消融技术

老虎油有优

03-12

这篇文章不错，转发给大家看看

Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology

老虎油有优

03-11

出海又一里程碑！！

Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology

老虎油有优

01-24

这篇文章不错，转发给大家看看

Baird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference

老虎油有优

01-21

太可怕了吧

苏州一械企，节前猛涨624%

老虎油有优

01-15

要是在底部进来就好了

@美港股观察社:底部爆拉近10倍，百德医疗缘何大涨？

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4164516241480402","uuid":"4164516241480402","gmtCreate":1701413115558,"gmtModify":1736853433245,"name":"老虎油有优","pinyin":"lhyyylaohuyouyouyou","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":417352781754760,"gmtCreate":1742912195075,"gmtModify":1742912196206,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/417352781754760","repostId":"417146387345480","repostType":1,"repost":{"id":417146387345480,"gmtCreate":1742871013650,"gmtModify":1742871506946,"author":{"id":"3524106587938986","authorId":"3524106587938986","name":"资本要闻","avatar":"https://static.tigerbbs.com/4b73ab963c29c77d538b8de17c26e931","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3524106587938986","authorIdStr":"3524106587938986"},"themes":[],"title":"美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学的保罗·威廉·拉登森教授莅临中肿超声科交流甲状腺消融技术","htmlText":"美国甲状腺协会（ATA）前主席莅临中肿超声科近日，美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学医学院保罗·威廉·拉登森教授莅临中肿超声科进行甲状腺消融技术交流，同行专家有南方科技大学医学院首任院长邢明照教授。专家简介保罗·威廉·拉登森教授 Paul William Ladenson保罗·威廉·拉登森教授是美国甲状腺协会 (ATA)前主席，现任约翰·霍普金斯大学医学院 约翰·伊格·霍华德内分泌与代谢学教授。保罗·威廉·拉登森教授同时兼任肿瘤学、病理学以及放射学与放射科学教授，临床专长是甲状腺疾病、内分泌与代谢紊乱。他于1988年创立了约翰霍普金斯甲状腺肿瘤中心，且担任了首任主任、《临床内分泌与代谢杂志》主编，以及美国内科医学委员会内分泌学、糖尿病和代谢学考试委员会主席。2012年，在美国甲状腺协会（ATA）第82届年会上，保罗·威廉·拉登森教授荣获路易斯·E·布拉弗曼讲座奖。来访专家观摩我院超声引导下甲状腺结节消融在中山大学肿瘤防治中心超声科主任周建华教授的带领下，来访专家来到超声介入室现场观摩了王建伟教授实施的两台甲状腺良性大结节消融微创手术，王建伟教授以娴熟的手法、精准的超声引导，不到30分钟完成一台5cm甲状腺良性大结节完全消融。保罗·威廉·拉登森教授对甲状腺消融手术的精准性和微创性感到惊讶：仅需局部麻醉、无需任何镇静药物、术毕患者面带微笑离开介入室。周建华教授向两位来访教授详细介绍了甲状腺结节消融适应症、术中超声实时引导技术、并发症、术后随访、消融疗效等细节。邢明照教授（左）周建华教授（中间）保罗·威廉·拉登森教授（右一）探讨与学习在随后的学习室深入交流中，双方紧密围绕“甲状腺良性结节以及甲状腺微小乳头状癌消融治疗”的主题展开了热烈的讨论。保罗·威廉·拉登森教授分享了ATA指南在该领域的最新进展，并指出甲状腺结节消融微创、有效、康复快、费用便宜等优点，给患者带来","listText":"美国甲状腺协会（ATA）前主席莅临中肿超声科近日，美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学医学院保罗·威廉·拉登森教授莅临中肿超声科进行甲状腺消融技术交流，同行专家有南方科技大学医学院首任院长邢明照教授。专家简介保罗·威廉·拉登森教授 Paul William Ladenson保罗·威廉·拉登森教授是美国甲状腺协会 (ATA)前主席，现任约翰·霍普金斯大学医学院 约翰·伊格·霍华德内分泌与代谢学教授。保罗·威廉·拉登森教授同时兼任肿瘤学、病理学以及放射学与放射科学教授，临床专长是甲状腺疾病、内分泌与代谢紊乱。他于1988年创立了约翰霍普金斯甲状腺肿瘤中心，且担任了首任主任、《临床内分泌与代谢杂志》主编，以及美国内科医学委员会内分泌学、糖尿病和代谢学考试委员会主席。2012年，在美国甲状腺协会（ATA）第82届年会上，保罗·威廉·拉登森教授荣获路易斯·E·布拉弗曼讲座奖。来访专家观摩我院超声引导下甲状腺结节消融在中山大学肿瘤防治中心超声科主任周建华教授的带领下，来访专家来到超声介入室现场观摩了王建伟教授实施的两台甲状腺良性大结节消融微创手术，王建伟教授以娴熟的手法、精准的超声引导，不到30分钟完成一台5cm甲状腺良性大结节完全消融。保罗·威廉·拉登森教授对甲状腺消融手术的精准性和微创性感到惊讶：仅需局部麻醉、无需任何镇静药物、术毕患者面带微笑离开介入室。周建华教授向两位来访教授详细介绍了甲状腺结节消融适应症、术中超声实时引导技术、并发症、术后随访、消融疗效等细节。邢明照教授（左）周建华教授（中间）保罗·威廉·拉登森教授（右一）探讨与学习在随后的学习室深入交流中，双方紧密围绕“甲状腺良性结节以及甲状腺微小乳头状癌消融治疗”的主题展开了热烈的讨论。保罗·威廉·拉登森教授分享了ATA指南在该领域的最新进展，并指出甲状腺结节消融微创、有效、康复快、费用便宜等优点，给患者带来","text":"美国甲状腺协会（ATA）前主席莅临中肿超声科近日，美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学医学院保罗·威廉·拉登森教授莅临中肿超声科进行甲状腺消融技术交流，同行专家有南方科技大学医学院首任院长邢明照教授。专家简介保罗·威廉·拉登森教授 Paul William Ladenson保罗·威廉·拉登森教授是美国甲状腺协会 (ATA)前主席，现任约翰·霍普金斯大学医学院 约翰·伊格·霍华德内分泌与代谢学教授。保罗·威廉·拉登森教授同时兼任肿瘤学、病理学以及放射学与放射科学教授，临床专长是甲状腺疾病、内分泌与代谢紊乱。他于1988年创立了约翰霍普金斯甲状腺肿瘤中心，且担任了首任主任、《临床内分泌与代谢杂志》主编，以及美国内科医学委员会内分泌学、糖尿病和代谢学考试委员会主席。2012年，在美国甲状腺协会（ATA）第82届年会上，保罗·威廉·拉登森教授荣获路易斯·E·布拉弗曼讲座奖。来访专家观摩我院超声引导下甲状腺结节消融在中山大学肿瘤防治中心超声科主任周建华教授的带领下，来访专家来到超声介入室现场观摩了王建伟教授实施的两台甲状腺良性大结节消融微创手术，王建伟教授以娴熟的手法、精准的超声引导，不到30分钟完成一台5cm甲状腺良性大结节完全消融。保罗·威廉·拉登森教授对甲状腺消融手术的精准性和微创性感到惊讶：仅需局部麻醉、无需任何镇静药物、术毕患者面带微笑离开介入室。周建华教授向两位来访教授详细介绍了甲状腺结节消融适应症、术中超声实时引导技术、并发症、术后随访、消融疗效等细节。邢明照教授（左）周建华教授（中间）保罗·威廉·拉登森教授（右一）探讨与学习在随后的学习室深入交流中，双方紧密围绕“甲状腺良性结节以及甲状腺微小乳头状癌消融治疗”的主题展开了热烈的讨论。保罗·威廉·拉登森教授分享了ATA指南在该领域的最新进展，并指出甲状腺结节消融微创、有效、康复快、费用便宜等优点，给患者带来","images":[{"img":"https://static.tigerbbs.com/516ea03a6f5f66016e230fed72bf7bb1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/417146387345480","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":9,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":412676184248664,"gmtCreate":1741789935594,"gmtModify":1741789937516,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/412676184248664","repostId":"1130988240","repostType":2,"repost":{"id":"1130988240","kind":"news","pubTimestamp":1741663125,"share":"https://www.laohu8.com/m/news/1130988240?lang=&edition=full","pubTime":"2025-03-11 11:18","market":"us","language":"zh","title":"Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1130988240","media":"prnewswire","summary":"NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered ","content":"<p>NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology,&nbsp;has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9388879624c7550954787a98e66028e9\" alt=\"Baird Indonesian Certificate\" title=\"Baird Indonesian Certificate\" tg-width=\"1000\" tg-height=\"750\"><span>Baird Indonesian Certificate</span></p><p>Baird Indonesian Certificate</p><p>\"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies,\" said Haimei Wu, Chairwoman of Baird Medical. &nbsp;\"We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.</p><p>Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.</p><p>With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.</p><p><strong>About Baird Medical</strong></p><p>Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.</p><p>Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.</p><p>The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</p>","source":"prnewswire","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-11 11:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime><strong>prnewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered ...</p>\n\n<a href=\"https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BDMD":"百德医疗"},"source_url":"https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130988240","content_text":"NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.Baird Indonesian CertificateBaird Indonesian Certificate\"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies,\" said Haimei Wu, Chairwoman of Baird Medical.  \"We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.About Baird MedicalBaird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.","news_type":1,"symbols_score_info":{"BDMD":1.1}},"isVote":1,"tweetType":1,"viewCount":807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":412266188300904,"gmtCreate":1741671740490,"gmtModify":1741673434846,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"出海又一里程碑！！","listText":"出海又一里程碑！！","text":"出海又一里程碑！！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/412266188300904","repostId":"1130988240","repostType":2,"repost":{"id":"1130988240","kind":"news","pubTimestamp":1741663125,"share":"https://www.laohu8.com/m/news/1130988240?lang=&edition=full","pubTime":"2025-03-11 11:18","market":"us","language":"zh","title":"Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1130988240","media":"prnewswire","summary":"NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered ","content":"<p>NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology,&nbsp;has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9388879624c7550954787a98e66028e9\" alt=\"Baird Indonesian Certificate\" title=\"Baird Indonesian Certificate\" tg-width=\"1000\" tg-height=\"750\"><span>Baird Indonesian Certificate</span></p><p>Baird Indonesian Certificate</p><p>\"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies,\" said Haimei Wu, Chairwoman of Baird Medical. &nbsp;\"We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.</p><p>Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.</p><p>With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.</p><p><strong>About Baird Medical</strong></p><p>Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.</p><p>Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.</p><p>The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</p>","source":"prnewswire","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-11 11:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime><strong>prnewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered ...</p>\n\n<a href=\"https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BDMD":"百德医疗"},"source_url":"https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130988240","content_text":"NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.Baird Indonesian CertificateBaird Indonesian Certificate\"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies,\" said Haimei Wu, Chairwoman of Baird Medical.  \"We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.About Baird MedicalBaird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.","news_type":1,"symbols_score_info":{"BDMD":1.1}},"isVote":1,"tweetType":1,"viewCount":927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":396017971991184,"gmtCreate":1737706319758,"gmtModify":1737706434276,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/396017971991184","repostId":"1126482238","repostType":2,"repost":{"id":"1126482238","kind":"news","pubTimestamp":1737352729,"share":"https://www.laohu8.com/m/news/1126482238?lang=&edition=full","pubTime":"2025-01-20 13:58","market":"us","language":"zh","title":"Baird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1126482238","media":"prnewswire","summary":"NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (\"Baird Medical\" or the \"Company\"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in Sa","content":"<p>NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (\"Baird Medical\" or the \"Company\"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in San Francisco amid the 2025 J.P. Morgan Healthcare Conference, one of the most prominent healthcare investment gatherings globally.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51ca624f4a0d15b9a07ef36685d4d558\" alt=\"J.P. Morgan Healthcare Conference\" title=\"J.P. Morgan Healthcare Conference\" tg-width=\"1000\" tg-height=\"750\"><span>J.P. Morgan Healthcare Conference</span></p><p>Following its successful debut on Nasdaq in October 2024, Baird Medical connected with healthcare investors and industry leaders during the week of the conference, engaging in meaningful discussions on the company's advancements in microwave ablation technology and its commitment to improving patient outcomes.</p><p>\"Being in San Francisco during the J.P. Morgan Healthcare Conference provided a valuable opportunity to engage with shareholders, innovators, and advisors in the healthcare sector,\" said Haimei Wu, Chairwoman of Baird Medical. \"These discussions allowed us to share our vision for growth and innovation in the years ahead.\"</p><p>Looking ahead, Baird Medical remains committed to leveraging the insights and relationships gained from these interactions to drive its 2025 strategic initiatives. The company will continue expanding its U.S. footprint and collaborating with key opinion leaders (KOLs) who share its mission of enhancing patient care through cutting-edge medical technology.</p><p><strong>About Baird Medical</strong><br>Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit <strong><u>https://bairdmed.com/</u></strong></p><p><strong>Forward-Looking Statements<br></strong>This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as \"may,\" \"might,\" \"will,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential,\" \"continue,\" or the negative of these terms or other similar expressions.</p><p>These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.</p><p>Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.</p><p>Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.</p><p>SOURCE BDMD</p>","source":"prnewswire","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-20 13:58 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.prnewswire.com/news-releases/baird-medical-engages-with-healthcare-leaders-amid-2025-jp-morgan-healthcare-conference-302353999.html?tc=eml_cleartime><strong>prnewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (\"Baird Medical\" or the \"Company\"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in ...</p>\n\n<a href=\"https://www.prnewswire.com/news-releases/baird-medical-engages-with-healthcare-leaders-amid-2025-jp-morgan-healthcare-conference-302353999.html?tc=eml_cleartime\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BDMD":"百德医疗"},"source_url":"https://www.prnewswire.com/news-releases/baird-medical-engages-with-healthcare-leaders-amid-2025-jp-morgan-healthcare-conference-302353999.html?tc=eml_cleartime","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126482238","content_text":"NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (\"Baird Medical\" or the \"Company\"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in San Francisco amid the 2025 J.P. Morgan Healthcare Conference, one of the most prominent healthcare investment gatherings globally.J.P. Morgan Healthcare ConferenceFollowing its successful debut on Nasdaq in October 2024, Baird Medical connected with healthcare investors and industry leaders during the week of the conference, engaging in meaningful discussions on the company's advancements in microwave ablation technology and its commitment to improving patient outcomes.\"Being in San Francisco during the J.P. Morgan Healthcare Conference provided a valuable opportunity to engage with shareholders, innovators, and advisors in the healthcare sector,\" said Haimei Wu, Chairwoman of Baird Medical. \"These discussions allowed us to share our vision for growth and innovation in the years ahead.\"Looking ahead, Baird Medical remains committed to leveraging the insights and relationships gained from these interactions to drive its 2025 strategic initiatives. The company will continue expanding its U.S. footprint and collaborating with key opinion leaders (KOLs) who share its mission of enhancing patient care through cutting-edge medical technology.About Baird MedicalBaird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as \"may,\" \"might,\" \"will,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential,\" \"continue,\" or the negative of these terms or other similar expressions.These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.SOURCE BDMD","news_type":1,"symbols_score_info":{"BDMD":1.1}},"isVote":1,"tweetType":1,"viewCount":1018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":395099862028728,"gmtCreate":1737470268113,"gmtModify":1737471097294,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"太可怕了吧","listText":"太可怕了吧","text":"太可怕了吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/395099862028728","repostId":"2500994201","repostType":2,"repost":{"id":"2500994201","kind":"news","pubTimestamp":1735901580,"share":"https://www.laohu8.com/m/news/2500994201?lang=&edition=full","pubTime":"2025-01-03 18:53","market":"fut","language":"zh","title":"苏州一械企，节前猛涨624%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500994201","media":"医疗器械经销商...","summary":"截至该年的最后一个交易日，即12月31日，股价飙升了623.81%，从之前的低点1.05美元跃升至7.60美元。随着此次并购，百德医疗得以从传统的分销商转变为集研发与制造于一体的高科技医疗器械公司，正式进军微波消融市场。由于未能满足2021年的业绩承诺，百德医疗面临潜在的赔偿责任。在国内市场占据领先地位的百德医疗成功赴美上市，这一举动吸引了众多海外投资者的目光，并促成了其近日股价飙升超过600%。","content":"<p>美国时间2024年12月31日，<a href=\"https://laohu8.com/S/BDMD\">Baird Medical Investment Holdings Ltd</a>（下文简称“<a href=\"https://laohu8.com/S/06678\">百德医疗</a>”）股价飙升623.81%。百德医疗是百德（苏州）医疗有限公司实质控股公司。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e8bf7e3bba9de9add573fcec464443a\" tg-width=\"1078\" tg-height=\"245\"></p><p>百德医疗于2024年10月2日正式通过借壳SPAC（特殊目的收购公司）ExcelFin Acquisition（XFIN），在美国纳斯达克挂牌上市，是国内领先的微波消融医疗企业。据百德医疗资料显示，以2022年微波消融针的销售收入及销售数量计，百德医疗在中国治疗甲状腺结节及乳房肿块的微波消融医疗器材供应商中排名第一。此外，以2022年销售收入计算，该公司是中国第三大微波消融医疗器械供应商。</p><p>01</p><p>触底反弹</p><p>24年末的惊人逆转</p><p>上市首日，公司股票收盘价为每股6美元，市值定格在3850.39万美元。然而，在市场波动的影响下，百德的股价不久后跌至1.03美元的历史低位，相比其峰值接近10美元时，跌幅超过了80%，反映出投资者对行业趋势及宏观经济环境的担忧。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2c94bfddb64bfa781d7a4d9941555080\" tg-width=\"1080\" tg-height=\"626\"></p><p>然而，进入2024年的最后两周，百德医疗的股价走势出现了惊人的逆转。截至该年的最后一个交易日，即12月31日，股价飙升了623.81%，从之前的低点1.05美元跃升至7.60美元。当天，股票的交易区间宽幅震荡，从最低1.42美元到最高9.35美元，日内波幅达到了560.78%。过去两周内，股价累计涨幅达到了377.99%，而最后一天的成交量更是从前一日增加了8900万股，成交总额约为6.77亿美元。</p><p>这种积极的市场表现或许可以归因于百德医疗近期业务的快速扩展。根据最新的财务数据，公司在2024年上半年实现了显著的增长：总收入同比增长13.8%，达到1310万美元；净利润同比激增85.8%，达到440万美元；毛利润也上涨了20.9%。这些优异的成绩主要得益于其在中国市场的稳健发展以及在美国市场取得的初步成功。</p><p>02</p><p>突破美国市场</p><p>转型获FDA认证成功</p><p>成立于2012年的百德医疗，最初是一家专注于医疗器械销售的企业。然而，在2017年和2019年间，通过两次战略性的股权收购，百德医疗全资拥有了南京长城——一家在微波消融技术领域处于前沿位置的制造商，从而完成了业务转型。</p><p>南京长城早在上世纪80年代便已涉足医用微波治疗设备的研发工作，是国内该领域的先驱之一。随着此次并购，百德医疗得以从传统的分销商转变为集研发与制造于一体的高科技医疗器械公司，正式进军微波消融市场。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9cb8cad8d2fee3b2881d38209ee6a896\" tg-width=\"748\" tg-height=\"515\"></p><p>▲ 精细型微波消融针</p><p>微波消融技术是利用微波能量对细胞和组织进行热损伤处理以实现治疗效果的一种方法。借助于超声波或CT扫描等影像学手段的指引，医生可以通过微创方式将特制的微波消融针置入病变部位，启动微波消融装置后，可在短时间内完成肿瘤组织的消除。</p><p>鉴于其简便的操作流程、无需大切口以及较短的手术周期等特性，微波消融手术逐渐受到欢迎。随着微创技术的进步和普及，该疗法的应用范围也在不断扩大。</p><p>百德医疗提供的解决方案涵盖了多个治疗领域，包括但不限于甲状腺结节、乳腺结节、肝癌及肺癌的处理。根据公开资料，公司的产品线包含用于肝癌和甲状腺结节治疗的微波消融仪器与配套的消融针，既有标准型也有设计更为精密的型号。</p><p>根据2020年的市场表现，百德医疗与南京亿高、维京九州、南京康友共同被视为国内微波消融行业的四大主导力量。</p><p>值得注意的是，在2023年末，百德（苏州）医疗有限公司所生产的微波消融系统连同一次性使用的微波消融针成功获得了美国市场的准入资格，作为FDA II类监管器械开始在美国销售。</p><p>03</p><p>一波三折的上市历程</p><p>百德医疗经历了复杂且充满挑战的上市过程。2021年6月30日，公司成功完成了9440万元人民币的C轮融资，此轮融资后估值达到了8.38亿元人民币。参与投资的机构包括中银国际投资、CVC资本以及<a href=\"https://laohu8.com/S/00929\">国际精密</a>集团等。作为融资的一部分，百德医疗与中银国际达成了业绩承诺协议，约定在2021和2022财年实现特定的盈利目标；若未能达成，则需向中银国际提供补偿。</p><p>由于未能满足2021年的业绩承诺，百德医疗面临潜在的赔偿责任。然而，如果公司在2022年底之前能够成功上市，该业绩承诺将自动解除，这可能是促使百德医疗加快上市步伐的一个因素。</p><p>首次尝试是在2021年9月28日向<a href=\"https://laohu8.com/S/00388\">香港交易所</a>提交了上市申请，但最终未能成行。随后在2022年4月7日再次提交申请，并计划于同年10月5日在港交所上市。但是，在预定上市日期前几天的10月3日，百德医疗宣布推迟IPO。经过一段时间的调整，2023年6月26日，百德医疗选择通过与一家特殊目的收购公司（SPAC）——<a href=\"https://laohu8.com/S/XFINU\">ExcelFin Acquisition Corp.</a>合并的方式在美国寻求上市机会。</p><p>此次合并代表了百德医疗第三次冲击资本市场的机会。据透露，ExcelFin的赞助商Grand Fortune Capital同意从现有股东手中购买约880万美元的百德医疗债务，这可能与之前的业绩承诺相关。合并前百德医疗的股权价值为3亿美元，而合并后的预估企业价值约为3.7亿美元。原有股东持有的百德医疗股份将转换为新公司的普通股。</p><p>最终，2024年10月2日，百德医疗以Baird Medical Investment Holdings Limited的身份在美国市场挂牌上市。</p><p>在中国，微波消融治疗技术的应用处于世界领先地位，无论是临床实践还是设备制造方面均表现出色。根据智研咨询的数据，2022年全球热消融医疗服务市场的规模超过了120亿美元，其中微波消融占据了大约三分之一的份额，即约40亿美元。</p><p>在国内市场占据领先地位的百德医疗成功赴美上市，这一举动吸引了众多海外投资者的目光，并促成了其近日股价飙升超过600%。然而，在美股SPAC上市的医疗公司整体表现欠佳的背景下，百德医疗能否维持稳定的增长态势仍存疑问。对此，我们将持续跟踪报道，关注百德医疗未来的表现及市场反应。</p><p>海量资讯、精准解读，尽在新浪财经APP</p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>苏州一械企，节前猛涨624%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n苏州一械企，节前猛涨624%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-03 18:53 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/roll/2025-01-03/doc-inectaav1413200.shtml><strong>医疗器械经销商...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美国时间2024年12月31日，Baird Medical Investment Holdings Ltd（下文简称“百德医疗”）股价飙升623.81%。百德医疗是百德（苏州）医疗有限公司实质控股公司。百德医疗于2024年10月2日正式通过借壳SPAC（特殊目的收购公司）ExcelFin Acquisition（XFIN），在美国纳斯达克挂牌上市，是国内领先的微波消融医疗企业。据百德医疗资料显示，...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2025-01-03/doc-inectaav1413200.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.sina.com.cn/roll/2025-01-03/doc-inectaav1413200.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2500994201","content_text":"美国时间2024年12月31日，Baird Medical Investment Holdings Ltd（下文简称“百德医疗”）股价飙升623.81%。百德医疗是百德（苏州）医疗有限公司实质控股公司。百德医疗于2024年10月2日正式通过借壳SPAC（特殊目的收购公司）ExcelFin Acquisition（XFIN），在美国纳斯达克挂牌上市，是国内领先的微波消融医疗企业。据百德医疗资料显示，以2022年微波消融针的销售收入及销售数量计，百德医疗在中国治疗甲状腺结节及乳房肿块的微波消融医疗器材供应商中排名第一。此外，以2022年销售收入计算，该公司是中国第三大微波消融医疗器械供应商。01触底反弹24年末的惊人逆转上市首日，公司股票收盘价为每股6美元，市值定格在3850.39万美元。然而，在市场波动的影响下，百德的股价不久后跌至1.03美元的历史低位，相比其峰值接近10美元时，跌幅超过了80%，反映出投资者对行业趋势及宏观经济环境的担忧。然而，进入2024年的最后两周，百德医疗的股价走势出现了惊人的逆转。截至该年的最后一个交易日，即12月31日，股价飙升了623.81%，从之前的低点1.05美元跃升至7.60美元。当天，股票的交易区间宽幅震荡，从最低1.42美元到最高9.35美元，日内波幅达到了560.78%。过去两周内，股价累计涨幅达到了377.99%，而最后一天的成交量更是从前一日增加了8900万股，成交总额约为6.77亿美元。这种积极的市场表现或许可以归因于百德医疗近期业务的快速扩展。根据最新的财务数据，公司在2024年上半年实现了显著的增长：总收入同比增长13.8%，达到1310万美元；净利润同比激增85.8%，达到440万美元；毛利润也上涨了20.9%。这些优异的成绩主要得益于其在中国市场的稳健发展以及在美国市场取得的初步成功。02突破美国市场转型获FDA认证成功成立于2012年的百德医疗，最初是一家专注于医疗器械销售的企业。然而，在2017年和2019年间，通过两次战略性的股权收购，百德医疗全资拥有了南京长城——一家在微波消融技术领域处于前沿位置的制造商，从而完成了业务转型。南京长城早在上世纪80年代便已涉足医用微波治疗设备的研发工作，是国内该领域的先驱之一。随着此次并购，百德医疗得以从传统的分销商转变为集研发与制造于一体的高科技医疗器械公司，正式进军微波消融市场。▲ 精细型微波消融针微波消融技术是利用微波能量对细胞和组织进行热损伤处理以实现治疗效果的一种方法。借助于超声波或CT扫描等影像学手段的指引，医生可以通过微创方式将特制的微波消融针置入病变部位，启动微波消融装置后，可在短时间内完成肿瘤组织的消除。鉴于其简便的操作流程、无需大切口以及较短的手术周期等特性，微波消融手术逐渐受到欢迎。随着微创技术的进步和普及，该疗法的应用范围也在不断扩大。百德医疗提供的解决方案涵盖了多个治疗领域，包括但不限于甲状腺结节、乳腺结节、肝癌及肺癌的处理。根据公开资料，公司的产品线包含用于肝癌和甲状腺结节治疗的微波消融仪器与配套的消融针，既有标准型也有设计更为精密的型号。根据2020年的市场表现，百德医疗与南京亿高、维京九州、南京康友共同被视为国内微波消融行业的四大主导力量。值得注意的是，在2023年末，百德（苏州）医疗有限公司所生产的微波消融系统连同一次性使用的微波消融针成功获得了美国市场的准入资格，作为FDA II类监管器械开始在美国销售。03一波三折的上市历程百德医疗经历了复杂且充满挑战的上市过程。2021年6月30日，公司成功完成了9440万元人民币的C轮融资，此轮融资后估值达到了8.38亿元人民币。参与投资的机构包括中银国际投资、CVC资本以及国际精密集团等。作为融资的一部分，百德医疗与中银国际达成了业绩承诺协议，约定在2021和2022财年实现特定的盈利目标；若未能达成，则需向中银国际提供补偿。由于未能满足2021年的业绩承诺，百德医疗面临潜在的赔偿责任。然而，如果公司在2022年底之前能够成功上市，该业绩承诺将自动解除，这可能是促使百德医疗加快上市步伐的一个因素。首次尝试是在2021年9月28日向香港交易所提交了上市申请，但最终未能成行。随后在2022年4月7日再次提交申请，并计划于同年10月5日在港交所上市。但是，在预定上市日期前几天的10月3日，百德医疗宣布推迟IPO。经过一段时间的调整，2023年6月26日，百德医疗选择通过与一家特殊目的收购公司（SPAC）——ExcelFin Acquisition Corp.合并的方式在美国寻求上市机会。此次合并代表了百德医疗第三次冲击资本市场的机会。据透露，ExcelFin的赞助商Grand Fortune Capital同意从现有股东手中购买约880万美元的百德医疗债务，这可能与之前的业绩承诺相关。合并前百德医疗的股权价值为3亿美元，而合并后的预估企业价值约为3.7亿美元。原有股东持有的百德医疗股份将转换为新公司的普通股。最终，2024年10月2日，百德医疗以Baird Medical Investment Holdings Limited的身份在美国市场挂牌上市。在中国，微波消融治疗技术的应用处于世界领先地位，无论是临床实践还是设备制造方面均表现出色。根据智研咨询的数据，2022年全球热消融医疗服务市场的规模超过了120亿美元，其中微波消融占据了大约三分之一的份额，即约40亿美元。在国内市场占据领先地位的百德医疗成功赴美上市，这一举动吸引了众多海外投资者的目光，并促成了其近日股价飙升超过600%。然而，在美股SPAC上市的医疗公司整体表现欠佳的背景下，百德医疗能否维持稳定的增长态势仍存疑问。对此，我们将持续跟踪报道，关注百德医疗未来的表现及市场反应。海量资讯、精准解读，尽在新浪财经APP","news_type":1,"symbols_score_info":{"BDMD":0.9}},"isVote":1,"tweetType":1,"viewCount":1427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":392684520895008,"gmtCreate":1736915822676,"gmtModify":1736917538056,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"要是在底部进来就好了","listText":"要是在底部进来就好了","text":"要是在底部进来就好了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/392684520895008","repostId":"392476442398944","repostType":1,"repost":{"id":392476442398944,"gmtCreate":1736843474792,"gmtModify":1736848924720,"author":{"id":"3519157433193136","authorId":"3519157433193136","name":"美港股观察社","avatar":"https://static.tigerbbs.com/cfcc85fddcd77379cda6138d51be4c17","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519157433193136","authorIdStr":"3519157433193136"},"themes":[],"title":"底部爆拉近10倍，百德医疗缘何大涨？","htmlText":"从2024年12月31日开始，百德医疗开启连续上涨，截至2025年1月13日，公司股价在底部暴涨近10倍，吸引了投资者的广泛关注。这家公司有着怎样的背景，又为何被市场如此看好呢？让我们一探究竟。 国内领先的微波消融医疗器械供应商 百德医疗投资有限公司成立于 2012 年，总部位于中国苏州太仓港区。其境内运营实体为百德（苏州）医疗有限公司，专注于微波消融（MWA）医疗器械的研发、生产和销售。百德医疗的微波消融医疗器械已经在国内成功注册为第三类医疗器械，并且在2023年11月，公司子公司百德（苏州）医疗有限公司获得美国食品药品监督管理局FDA 510k 批准，其微波消融系统和一次性产品组合微波消融针在美国作为监管II类设备。根据弗若斯特沙利文的资料，按2022年微波消融针的销售收入和销售量计算，百德医疗是中国治疗甲状腺结节及乳腺肿块的微波消融医疗器械第一大供应商，而按照2022年销售收入计算，百德医疗是中国第三大微波消融医疗器械供应商。 2024 年初，百德医疗成功获得了中国证监会关于境外发行上市的备案通知，达成迈向国际资本市场的重要一步。随后在9月，公司完成了与 Excel Fin Acquisition Corp 的合并交易，并在10月2日成功在纳斯达克上市，并更名为“Baird Medical Investment Holdings Limited”，股票代码为“BDMD”。 微波消融技术市场空间大 上市后，百德医疗的股价并不理想，但是，其长期的增长前景正逐渐被市场所认知。百德医疗的产品包括微波消融治疗仪及与治疗仪配合使用微波消融针，通过向医疗机构销售相关产品获得收入。微波消融疗法是利用微波电磁场产热而使局部细胞组织坏死，其常见适应症包括甲状腺结节及甲状腺癌、乳腺结节、肝癌、肺结节及肺癌。相比开放性手术、化疗及放疗等，微波消融治疗临床效果令人满意，而费用更低，能够减轻患者","listText":"从2024年12月31日开始，百德医疗开启连续上涨，截至2025年1月13日，公司股价在底部暴涨近10倍，吸引了投资者的广泛关注。这家公司有着怎样的背景，又为何被市场如此看好呢？让我们一探究竟。 国内领先的微波消融医疗器械供应商 百德医疗投资有限公司成立于 2012 年，总部位于中国苏州太仓港区。其境内运营实体为百德（苏州）医疗有限公司，专注于微波消融（MWA）医疗器械的研发、生产和销售。百德医疗的微波消融医疗器械已经在国内成功注册为第三类医疗器械，并且在2023年11月，公司子公司百德（苏州）医疗有限公司获得美国食品药品监督管理局FDA 510k 批准，其微波消融系统和一次性产品组合微波消融针在美国作为监管II类设备。根据弗若斯特沙利文的资料，按2022年微波消融针的销售收入和销售量计算，百德医疗是中国治疗甲状腺结节及乳腺肿块的微波消融医疗器械第一大供应商，而按照2022年销售收入计算，百德医疗是中国第三大微波消融医疗器械供应商。 2024 年初，百德医疗成功获得了中国证监会关于境外发行上市的备案通知，达成迈向国际资本市场的重要一步。随后在9月，公司完成了与 Excel Fin Acquisition Corp 的合并交易，并在10月2日成功在纳斯达克上市，并更名为“Baird Medical Investment Holdings Limited”，股票代码为“BDMD”。 微波消融技术市场空间大 上市后，百德医疗的股价并不理想，但是，其长期的增长前景正逐渐被市场所认知。百德医疗的产品包括微波消融治疗仪及与治疗仪配合使用微波消融针，通过向医疗机构销售相关产品获得收入。微波消融疗法是利用微波电磁场产热而使局部细胞组织坏死，其常见适应症包括甲状腺结节及甲状腺癌、乳腺结节、肝癌、肺结节及肺癌。相比开放性手术、化疗及放疗等，微波消融治疗临床效果令人满意，而费用更低，能够减轻患者","text":"从2024年12月31日开始，百德医疗开启连续上涨，截至2025年1月13日，公司股价在底部暴涨近10倍，吸引了投资者的广泛关注。这家公司有着怎样的背景，又为何被市场如此看好呢？让我们一探究竟。 国内领先的微波消融医疗器械供应商 百德医疗投资有限公司成立于 2012 年，总部位于中国苏州太仓港区。其境内运营实体为百德（苏州）医疗有限公司，专注于微波消融（MWA）医疗器械的研发、生产和销售。百德医疗的微波消融医疗器械已经在国内成功注册为第三类医疗器械，并且在2023年11月，公司子公司百德（苏州）医疗有限公司获得美国食品药品监督管理局FDA 510k 批准，其微波消融系统和一次性产品组合微波消融针在美国作为监管II类设备。根据弗若斯特沙利文的资料，按2022年微波消融针的销售收入和销售量计算，百德医疗是中国治疗甲状腺结节及乳腺肿块的微波消融医疗器械第一大供应商，而按照2022年销售收入计算，百德医疗是中国第三大微波消融医疗器械供应商。 2024 年初，百德医疗成功获得了中国证监会关于境外发行上市的备案通知，达成迈向国际资本市场的重要一步。随后在9月，公司完成了与 Excel Fin Acquisition Corp 的合并交易，并在10月2日成功在纳斯达克上市，并更名为“Baird Medical Investment Holdings Limited”，股票代码为“BDMD”。 微波消融技术市场空间大 上市后，百德医疗的股价并不理想，但是，其长期的增长前景正逐渐被市场所认知。百德医疗的产品包括微波消融治疗仪及与治疗仪配合使用微波消融针，通过向医疗机构销售相关产品获得收入。微波消融疗法是利用微波电磁场产热而使局部细胞组织坏死，其常见适应症包括甲状腺结节及甲状腺癌、乳腺结节、肝癌、肺结节及肺癌。相比开放性手术、化疗及放疗等，微波消融治疗临床效果令人满意，而费用更低，能够减轻患者","images":[{"img":"https://static.tigerbbs.com/2df824769405b0aec3f33f4a8555e283","width":"1345","height":"698"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/392476442398944","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2055,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":417352781754760,"gmtCreate":1742912195075,"gmtModify":1742912196206,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/417352781754760","repostId":"417146387345480","repostType":1,"repost":{"id":417146387345480,"gmtCreate":1742871013650,"gmtModify":1742871506946,"author":{"id":"3524106587938986","authorId":"3524106587938986","name":"资本要闻","avatar":"https://static.tigerbbs.com/4b73ab963c29c77d538b8de17c26e931","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3524106587938986","authorIdStr":"3524106587938986"},"themes":[],"title":"美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学的保罗·威廉·拉登森教授莅临中肿超声科交流甲状腺消融技术","htmlText":"美国甲状腺协会（ATA）前主席莅临中肿超声科近日，美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学医学院保罗·威廉·拉登森教授莅临中肿超声科进行甲状腺消融技术交流，同行专家有南方科技大学医学院首任院长邢明照教授。专家简介保罗·威廉·拉登森教授 Paul William Ladenson保罗·威廉·拉登森教授是美国甲状腺协会 (ATA)前主席，现任约翰·霍普金斯大学医学院 约翰·伊格·霍华德内分泌与代谢学教授。保罗·威廉·拉登森教授同时兼任肿瘤学、病理学以及放射学与放射科学教授，临床专长是甲状腺疾病、内分泌与代谢紊乱。他于1988年创立了约翰霍普金斯甲状腺肿瘤中心，且担任了首任主任、《临床内分泌与代谢杂志》主编，以及美国内科医学委员会内分泌学、糖尿病和代谢学考试委员会主席。2012年，在美国甲状腺协会（ATA）第82届年会上，保罗·威廉·拉登森教授荣获路易斯·E·布拉弗曼讲座奖。来访专家观摩我院超声引导下甲状腺结节消融在中山大学肿瘤防治中心超声科主任周建华教授的带领下，来访专家来到超声介入室现场观摩了王建伟教授实施的两台甲状腺良性大结节消融微创手术，王建伟教授以娴熟的手法、精准的超声引导，不到30分钟完成一台5cm甲状腺良性大结节完全消融。保罗·威廉·拉登森教授对甲状腺消融手术的精准性和微创性感到惊讶：仅需局部麻醉、无需任何镇静药物、术毕患者面带微笑离开介入室。周建华教授向两位来访教授详细介绍了甲状腺结节消融适应症、术中超声实时引导技术、并发症、术后随访、消融疗效等细节。邢明照教授（左）周建华教授（中间）保罗·威廉·拉登森教授（右一）探讨与学习在随后的学习室深入交流中，双方紧密围绕“甲状腺良性结节以及甲状腺微小乳头状癌消融治疗”的主题展开了热烈的讨论。保罗·威廉·拉登森教授分享了ATA指南在该领域的最新进展，并指出甲状腺结节消融微创、有效、康复快、费用便宜等优点，给患者带来","listText":"美国甲状腺协会（ATA）前主席莅临中肿超声科近日，美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学医学院保罗·威廉·拉登森教授莅临中肿超声科进行甲状腺消融技术交流，同行专家有南方科技大学医学院首任院长邢明照教授。专家简介保罗·威廉·拉登森教授 Paul William Ladenson保罗·威廉·拉登森教授是美国甲状腺协会 (ATA)前主席，现任约翰·霍普金斯大学医学院 约翰·伊格·霍华德内分泌与代谢学教授。保罗·威廉·拉登森教授同时兼任肿瘤学、病理学以及放射学与放射科学教授，临床专长是甲状腺疾病、内分泌与代谢紊乱。他于1988年创立了约翰霍普金斯甲状腺肿瘤中心，且担任了首任主任、《临床内分泌与代谢杂志》主编，以及美国内科医学委员会内分泌学、糖尿病和代谢学考试委员会主席。2012年，在美国甲状腺协会（ATA）第82届年会上，保罗·威廉·拉登森教授荣获路易斯·E·布拉弗曼讲座奖。来访专家观摩我院超声引导下甲状腺结节消融在中山大学肿瘤防治中心超声科主任周建华教授的带领下，来访专家来到超声介入室现场观摩了王建伟教授实施的两台甲状腺良性大结节消融微创手术，王建伟教授以娴熟的手法、精准的超声引导，不到30分钟完成一台5cm甲状腺良性大结节完全消融。保罗·威廉·拉登森教授对甲状腺消融手术的精准性和微创性感到惊讶：仅需局部麻醉、无需任何镇静药物、术毕患者面带微笑离开介入室。周建华教授向两位来访教授详细介绍了甲状腺结节消融适应症、术中超声实时引导技术、并发症、术后随访、消融疗效等细节。邢明照教授（左）周建华教授（中间）保罗·威廉·拉登森教授（右一）探讨与学习在随后的学习室深入交流中，双方紧密围绕“甲状腺良性结节以及甲状腺微小乳头状癌消融治疗”的主题展开了热烈的讨论。保罗·威廉·拉登森教授分享了ATA指南在该领域的最新进展，并指出甲状腺结节消融微创、有效、康复快、费用便宜等优点，给患者带来","text":"美国甲状腺协会（ATA）前主席莅临中肿超声科近日，美国甲状腺协会（ATA）前主席、约翰·霍普金斯大学医学院保罗·威廉·拉登森教授莅临中肿超声科进行甲状腺消融技术交流，同行专家有南方科技大学医学院首任院长邢明照教授。专家简介保罗·威廉·拉登森教授 Paul William Ladenson保罗·威廉·拉登森教授是美国甲状腺协会 (ATA)前主席，现任约翰·霍普金斯大学医学院 约翰·伊格·霍华德内分泌与代谢学教授。保罗·威廉·拉登森教授同时兼任肿瘤学、病理学以及放射学与放射科学教授，临床专长是甲状腺疾病、内分泌与代谢紊乱。他于1988年创立了约翰霍普金斯甲状腺肿瘤中心，且担任了首任主任、《临床内分泌与代谢杂志》主编，以及美国内科医学委员会内分泌学、糖尿病和代谢学考试委员会主席。2012年，在美国甲状腺协会（ATA）第82届年会上，保罗·威廉·拉登森教授荣获路易斯·E·布拉弗曼讲座奖。来访专家观摩我院超声引导下甲状腺结节消融在中山大学肿瘤防治中心超声科主任周建华教授的带领下，来访专家来到超声介入室现场观摩了王建伟教授实施的两台甲状腺良性大结节消融微创手术，王建伟教授以娴熟的手法、精准的超声引导，不到30分钟完成一台5cm甲状腺良性大结节完全消融。保罗·威廉·拉登森教授对甲状腺消融手术的精准性和微创性感到惊讶：仅需局部麻醉、无需任何镇静药物、术毕患者面带微笑离开介入室。周建华教授向两位来访教授详细介绍了甲状腺结节消融适应症、术中超声实时引导技术、并发症、术后随访、消融疗效等细节。邢明照教授（左）周建华教授（中间）保罗·威廉·拉登森教授（右一）探讨与学习在随后的学习室深入交流中，双方紧密围绕“甲状腺良性结节以及甲状腺微小乳头状癌消融治疗”的主题展开了热烈的讨论。保罗·威廉·拉登森教授分享了ATA指南在该领域的最新进展，并指出甲状腺结节消融微创、有效、康复快、费用便宜等优点，给患者带来","images":[{"img":"https://static.tigerbbs.com/516ea03a6f5f66016e230fed72bf7bb1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/417146387345480","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":9,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":412676184248664,"gmtCreate":1741789935594,"gmtModify":1741789937516,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/412676184248664","repostId":"1130988240","repostType":2,"repost":{"id":"1130988240","kind":"news","pubTimestamp":1741663125,"share":"https://www.laohu8.com/m/news/1130988240?lang=&edition=full","pubTime":"2025-03-11 11:18","market":"us","language":"zh","title":"Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1130988240","media":"prnewswire","summary":"NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered ","content":"<p>NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology,&nbsp;has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9388879624c7550954787a98e66028e9\" alt=\"Baird Indonesian Certificate\" title=\"Baird Indonesian Certificate\" tg-width=\"1000\" tg-height=\"750\"><span>Baird Indonesian Certificate</span></p><p>Baird Indonesian Certificate</p><p>\"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies,\" said Haimei Wu, Chairwoman of Baird Medical. &nbsp;\"We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.</p><p>Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.</p><p>With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.</p><p><strong>About Baird Medical</strong></p><p>Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.</p><p>Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.</p><p>The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</p>","source":"prnewswire","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-11 11:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime><strong>prnewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered ...</p>\n\n<a href=\"https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BDMD":"百德医疗"},"source_url":"https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130988240","content_text":"NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.Baird Indonesian CertificateBaird Indonesian Certificate\"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies,\" said Haimei Wu, Chairwoman of Baird Medical.  \"We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.About Baird MedicalBaird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.","news_type":1,"symbols_score_info":{"BDMD":1.1}},"isVote":1,"tweetType":1,"viewCount":807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":412266188300904,"gmtCreate":1741671740490,"gmtModify":1741673434846,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"出海又一里程碑！！","listText":"出海又一里程碑！！","text":"出海又一里程碑！！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/412266188300904","repostId":"1130988240","repostType":2,"repost":{"id":"1130988240","kind":"news","pubTimestamp":1741663125,"share":"https://www.laohu8.com/m/news/1130988240?lang=&edition=full","pubTime":"2025-03-11 11:18","market":"us","language":"zh","title":"Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1130988240","media":"prnewswire","summary":"NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered ","content":"<p>NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology,&nbsp;has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9388879624c7550954787a98e66028e9\" alt=\"Baird Indonesian Certificate\" title=\"Baird Indonesian Certificate\" tg-width=\"1000\" tg-height=\"750\"><span>Baird Indonesian Certificate</span></p><p>Baird Indonesian Certificate</p><p>\"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies,\" said Haimei Wu, Chairwoman of Baird Medical. &nbsp;\"We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.</p><p>Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.</p><p>With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.</p><p><strong>About Baird Medical</strong></p><p>Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.</p><p>Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.</p><p>The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</p>","source":"prnewswire","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-11 11:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime><strong>prnewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered ...</p>\n\n<a href=\"https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BDMD":"百德医疗"},"source_url":"https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html?tc=eml_cleartime","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130988240","content_text":"NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.Baird Indonesian CertificateBaird Indonesian Certificate\"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies,\" said Haimei Wu, Chairwoman of Baird Medical.  \"We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.About Baird MedicalBaird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.","news_type":1,"symbols_score_info":{"BDMD":1.1}},"isVote":1,"tweetType":1,"viewCount":927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":396017971991184,"gmtCreate":1737706319758,"gmtModify":1737706434276,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/396017971991184","repostId":"1126482238","repostType":2,"repost":{"id":"1126482238","kind":"news","pubTimestamp":1737352729,"share":"https://www.laohu8.com/m/news/1126482238?lang=&edition=full","pubTime":"2025-01-20 13:58","market":"us","language":"zh","title":"Baird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1126482238","media":"prnewswire","summary":"NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (\"Baird Medical\" or the \"Company\"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in Sa","content":"<p>NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (\"Baird Medical\" or the \"Company\"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in San Francisco amid the 2025 J.P. Morgan Healthcare Conference, one of the most prominent healthcare investment gatherings globally.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51ca624f4a0d15b9a07ef36685d4d558\" alt=\"J.P. Morgan Healthcare Conference\" title=\"J.P. Morgan Healthcare Conference\" tg-width=\"1000\" tg-height=\"750\"><span>J.P. Morgan Healthcare Conference</span></p><p>Following its successful debut on Nasdaq in October 2024, Baird Medical connected with healthcare investors and industry leaders during the week of the conference, engaging in meaningful discussions on the company's advancements in microwave ablation technology and its commitment to improving patient outcomes.</p><p>\"Being in San Francisco during the J.P. Morgan Healthcare Conference provided a valuable opportunity to engage with shareholders, innovators, and advisors in the healthcare sector,\" said Haimei Wu, Chairwoman of Baird Medical. \"These discussions allowed us to share our vision for growth and innovation in the years ahead.\"</p><p>Looking ahead, Baird Medical remains committed to leveraging the insights and relationships gained from these interactions to drive its 2025 strategic initiatives. The company will continue expanding its U.S. footprint and collaborating with key opinion leaders (KOLs) who share its mission of enhancing patient care through cutting-edge medical technology.</p><p><strong>About Baird Medical</strong><br>Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit <strong><u>https://bairdmed.com/</u></strong></p><p><strong>Forward-Looking Statements<br></strong>This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as \"may,\" \"might,\" \"will,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential,\" \"continue,\" or the negative of these terms or other similar expressions.</p><p>These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.</p><p>Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.</p><p>Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.</p><p>SOURCE BDMD</p>","source":"prnewswire","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-20 13:58 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.prnewswire.com/news-releases/baird-medical-engages-with-healthcare-leaders-amid-2025-jp-morgan-healthcare-conference-302353999.html?tc=eml_cleartime><strong>prnewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (\"Baird Medical\" or the \"Company\"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in ...</p>\n\n<a href=\"https://www.prnewswire.com/news-releases/baird-medical-engages-with-healthcare-leaders-amid-2025-jp-morgan-healthcare-conference-302353999.html?tc=eml_cleartime\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BDMD":"百德医疗"},"source_url":"https://www.prnewswire.com/news-releases/baird-medical-engages-with-healthcare-leaders-amid-2025-jp-morgan-healthcare-conference-302353999.html?tc=eml_cleartime","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126482238","content_text":"NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (\"Baird Medical\" or the \"Company\"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in San Francisco amid the 2025 J.P. Morgan Healthcare Conference, one of the most prominent healthcare investment gatherings globally.J.P. Morgan Healthcare ConferenceFollowing its successful debut on Nasdaq in October 2024, Baird Medical connected with healthcare investors and industry leaders during the week of the conference, engaging in meaningful discussions on the company's advancements in microwave ablation technology and its commitment to improving patient outcomes.\"Being in San Francisco during the J.P. Morgan Healthcare Conference provided a valuable opportunity to engage with shareholders, innovators, and advisors in the healthcare sector,\" said Haimei Wu, Chairwoman of Baird Medical. \"These discussions allowed us to share our vision for growth and innovation in the years ahead.\"Looking ahead, Baird Medical remains committed to leveraging the insights and relationships gained from these interactions to drive its 2025 strategic initiatives. The company will continue expanding its U.S. footprint and collaborating with key opinion leaders (KOLs) who share its mission of enhancing patient care through cutting-edge medical technology.About Baird MedicalBaird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as \"may,\" \"might,\" \"will,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential,\" \"continue,\" or the negative of these terms or other similar expressions.These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.SOURCE BDMD","news_type":1,"symbols_score_info":{"BDMD":1.1}},"isVote":1,"tweetType":1,"viewCount":1018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":395099862028728,"gmtCreate":1737470268113,"gmtModify":1737471097294,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"太可怕了吧","listText":"太可怕了吧","text":"太可怕了吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/395099862028728","repostId":"2500994201","repostType":2,"repost":{"id":"2500994201","kind":"news","pubTimestamp":1735901580,"share":"https://www.laohu8.com/m/news/2500994201?lang=&edition=full","pubTime":"2025-01-03 18:53","market":"fut","language":"zh","title":"苏州一械企，节前猛涨624%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500994201","media":"医疗器械经销商...","summary":"截至该年的最后一个交易日，即12月31日，股价飙升了623.81%，从之前的低点1.05美元跃升至7.60美元。随着此次并购，百德医疗得以从传统的分销商转变为集研发与制造于一体的高科技医疗器械公司，正式进军微波消融市场。由于未能满足2021年的业绩承诺，百德医疗面临潜在的赔偿责任。在国内市场占据领先地位的百德医疗成功赴美上市，这一举动吸引了众多海外投资者的目光，并促成了其近日股价飙升超过600%。","content":"<p>美国时间2024年12月31日，<a href=\"https://laohu8.com/S/BDMD\">Baird Medical Investment Holdings Ltd</a>（下文简称“<a href=\"https://laohu8.com/S/06678\">百德医疗</a>”）股价飙升623.81%。百德医疗是百德（苏州）医疗有限公司实质控股公司。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e8bf7e3bba9de9add573fcec464443a\" tg-width=\"1078\" tg-height=\"245\"></p><p>百德医疗于2024年10月2日正式通过借壳SPAC（特殊目的收购公司）ExcelFin Acquisition（XFIN），在美国纳斯达克挂牌上市，是国内领先的微波消融医疗企业。据百德医疗资料显示，以2022年微波消融针的销售收入及销售数量计，百德医疗在中国治疗甲状腺结节及乳房肿块的微波消融医疗器材供应商中排名第一。此外，以2022年销售收入计算，该公司是中国第三大微波消融医疗器械供应商。</p><p>01</p><p>触底反弹</p><p>24年末的惊人逆转</p><p>上市首日，公司股票收盘价为每股6美元，市值定格在3850.39万美元。然而，在市场波动的影响下，百德的股价不久后跌至1.03美元的历史低位，相比其峰值接近10美元时，跌幅超过了80%，反映出投资者对行业趋势及宏观经济环境的担忧。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2c94bfddb64bfa781d7a4d9941555080\" tg-width=\"1080\" tg-height=\"626\"></p><p>然而，进入2024年的最后两周，百德医疗的股价走势出现了惊人的逆转。截至该年的最后一个交易日，即12月31日，股价飙升了623.81%，从之前的低点1.05美元跃升至7.60美元。当天，股票的交易区间宽幅震荡，从最低1.42美元到最高9.35美元，日内波幅达到了560.78%。过去两周内，股价累计涨幅达到了377.99%，而最后一天的成交量更是从前一日增加了8900万股，成交总额约为6.77亿美元。</p><p>这种积极的市场表现或许可以归因于百德医疗近期业务的快速扩展。根据最新的财务数据，公司在2024年上半年实现了显著的增长：总收入同比增长13.8%，达到1310万美元；净利润同比激增85.8%，达到440万美元；毛利润也上涨了20.9%。这些优异的成绩主要得益于其在中国市场的稳健发展以及在美国市场取得的初步成功。</p><p>02</p><p>突破美国市场</p><p>转型获FDA认证成功</p><p>成立于2012年的百德医疗，最初是一家专注于医疗器械销售的企业。然而，在2017年和2019年间，通过两次战略性的股权收购，百德医疗全资拥有了南京长城——一家在微波消融技术领域处于前沿位置的制造商，从而完成了业务转型。</p><p>南京长城早在上世纪80年代便已涉足医用微波治疗设备的研发工作，是国内该领域的先驱之一。随着此次并购，百德医疗得以从传统的分销商转变为集研发与制造于一体的高科技医疗器械公司，正式进军微波消融市场。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9cb8cad8d2fee3b2881d38209ee6a896\" tg-width=\"748\" tg-height=\"515\"></p><p>▲ 精细型微波消融针</p><p>微波消融技术是利用微波能量对细胞和组织进行热损伤处理以实现治疗效果的一种方法。借助于超声波或CT扫描等影像学手段的指引，医生可以通过微创方式将特制的微波消融针置入病变部位，启动微波消融装置后，可在短时间内完成肿瘤组织的消除。</p><p>鉴于其简便的操作流程、无需大切口以及较短的手术周期等特性，微波消融手术逐渐受到欢迎。随着微创技术的进步和普及，该疗法的应用范围也在不断扩大。</p><p>百德医疗提供的解决方案涵盖了多个治疗领域，包括但不限于甲状腺结节、乳腺结节、肝癌及肺癌的处理。根据公开资料，公司的产品线包含用于肝癌和甲状腺结节治疗的微波消融仪器与配套的消融针，既有标准型也有设计更为精密的型号。</p><p>根据2020年的市场表现，百德医疗与南京亿高、维京九州、南京康友共同被视为国内微波消融行业的四大主导力量。</p><p>值得注意的是，在2023年末，百德（苏州）医疗有限公司所生产的微波消融系统连同一次性使用的微波消融针成功获得了美国市场的准入资格，作为FDA II类监管器械开始在美国销售。</p><p>03</p><p>一波三折的上市历程</p><p>百德医疗经历了复杂且充满挑战的上市过程。2021年6月30日，公司成功完成了9440万元人民币的C轮融资，此轮融资后估值达到了8.38亿元人民币。参与投资的机构包括中银国际投资、CVC资本以及<a href=\"https://laohu8.com/S/00929\">国际精密</a>集团等。作为融资的一部分，百德医疗与中银国际达成了业绩承诺协议，约定在2021和2022财年实现特定的盈利目标；若未能达成，则需向中银国际提供补偿。</p><p>由于未能满足2021年的业绩承诺，百德医疗面临潜在的赔偿责任。然而，如果公司在2022年底之前能够成功上市，该业绩承诺将自动解除，这可能是促使百德医疗加快上市步伐的一个因素。</p><p>首次尝试是在2021年9月28日向<a href=\"https://laohu8.com/S/00388\">香港交易所</a>提交了上市申请，但最终未能成行。随后在2022年4月7日再次提交申请，并计划于同年10月5日在港交所上市。但是，在预定上市日期前几天的10月3日，百德医疗宣布推迟IPO。经过一段时间的调整，2023年6月26日，百德医疗选择通过与一家特殊目的收购公司（SPAC）——<a href=\"https://laohu8.com/S/XFINU\">ExcelFin Acquisition Corp.</a>合并的方式在美国寻求上市机会。</p><p>此次合并代表了百德医疗第三次冲击资本市场的机会。据透露，ExcelFin的赞助商Grand Fortune Capital同意从现有股东手中购买约880万美元的百德医疗债务，这可能与之前的业绩承诺相关。合并前百德医疗的股权价值为3亿美元，而合并后的预估企业价值约为3.7亿美元。原有股东持有的百德医疗股份将转换为新公司的普通股。</p><p>最终，2024年10月2日，百德医疗以Baird Medical Investment Holdings Limited的身份在美国市场挂牌上市。</p><p>在中国，微波消融治疗技术的应用处于世界领先地位，无论是临床实践还是设备制造方面均表现出色。根据智研咨询的数据，2022年全球热消融医疗服务市场的规模超过了120亿美元，其中微波消融占据了大约三分之一的份额，即约40亿美元。</p><p>在国内市场占据领先地位的百德医疗成功赴美上市，这一举动吸引了众多海外投资者的目光，并促成了其近日股价飙升超过600%。然而，在美股SPAC上市的医疗公司整体表现欠佳的背景下，百德医疗能否维持稳定的增长态势仍存疑问。对此，我们将持续跟踪报道，关注百德医疗未来的表现及市场反应。</p><p>海量资讯、精准解读，尽在新浪财经APP</p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>苏州一械企，节前猛涨624%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n苏州一械企，节前猛涨624%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-03 18:53 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/roll/2025-01-03/doc-inectaav1413200.shtml><strong>医疗器械经销商...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美国时间2024年12月31日，Baird Medical Investment Holdings Ltd（下文简称“百德医疗”）股价飙升623.81%。百德医疗是百德（苏州）医疗有限公司实质控股公司。百德医疗于2024年10月2日正式通过借壳SPAC（特殊目的收购公司）ExcelFin Acquisition（XFIN），在美国纳斯达克挂牌上市，是国内领先的微波消融医疗企业。据百德医疗资料显示，...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2025-01-03/doc-inectaav1413200.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.sina.com.cn/roll/2025-01-03/doc-inectaav1413200.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2500994201","content_text":"美国时间2024年12月31日，Baird Medical Investment Holdings Ltd（下文简称“百德医疗”）股价飙升623.81%。百德医疗是百德（苏州）医疗有限公司实质控股公司。百德医疗于2024年10月2日正式通过借壳SPAC（特殊目的收购公司）ExcelFin Acquisition（XFIN），在美国纳斯达克挂牌上市，是国内领先的微波消融医疗企业。据百德医疗资料显示，以2022年微波消融针的销售收入及销售数量计，百德医疗在中国治疗甲状腺结节及乳房肿块的微波消融医疗器材供应商中排名第一。此外，以2022年销售收入计算，该公司是中国第三大微波消融医疗器械供应商。01触底反弹24年末的惊人逆转上市首日，公司股票收盘价为每股6美元，市值定格在3850.39万美元。然而，在市场波动的影响下，百德的股价不久后跌至1.03美元的历史低位，相比其峰值接近10美元时，跌幅超过了80%，反映出投资者对行业趋势及宏观经济环境的担忧。然而，进入2024年的最后两周，百德医疗的股价走势出现了惊人的逆转。截至该年的最后一个交易日，即12月31日，股价飙升了623.81%，从之前的低点1.05美元跃升至7.60美元。当天，股票的交易区间宽幅震荡，从最低1.42美元到最高9.35美元，日内波幅达到了560.78%。过去两周内，股价累计涨幅达到了377.99%，而最后一天的成交量更是从前一日增加了8900万股，成交总额约为6.77亿美元。这种积极的市场表现或许可以归因于百德医疗近期业务的快速扩展。根据最新的财务数据，公司在2024年上半年实现了显著的增长：总收入同比增长13.8%，达到1310万美元；净利润同比激增85.8%，达到440万美元；毛利润也上涨了20.9%。这些优异的成绩主要得益于其在中国市场的稳健发展以及在美国市场取得的初步成功。02突破美国市场转型获FDA认证成功成立于2012年的百德医疗，最初是一家专注于医疗器械销售的企业。然而，在2017年和2019年间，通过两次战略性的股权收购，百德医疗全资拥有了南京长城——一家在微波消融技术领域处于前沿位置的制造商，从而完成了业务转型。南京长城早在上世纪80年代便已涉足医用微波治疗设备的研发工作，是国内该领域的先驱之一。随着此次并购，百德医疗得以从传统的分销商转变为集研发与制造于一体的高科技医疗器械公司，正式进军微波消融市场。▲ 精细型微波消融针微波消融技术是利用微波能量对细胞和组织进行热损伤处理以实现治疗效果的一种方法。借助于超声波或CT扫描等影像学手段的指引，医生可以通过微创方式将特制的微波消融针置入病变部位，启动微波消融装置后，可在短时间内完成肿瘤组织的消除。鉴于其简便的操作流程、无需大切口以及较短的手术周期等特性，微波消融手术逐渐受到欢迎。随着微创技术的进步和普及，该疗法的应用范围也在不断扩大。百德医疗提供的解决方案涵盖了多个治疗领域，包括但不限于甲状腺结节、乳腺结节、肝癌及肺癌的处理。根据公开资料，公司的产品线包含用于肝癌和甲状腺结节治疗的微波消融仪器与配套的消融针，既有标准型也有设计更为精密的型号。根据2020年的市场表现，百德医疗与南京亿高、维京九州、南京康友共同被视为国内微波消融行业的四大主导力量。值得注意的是，在2023年末，百德（苏州）医疗有限公司所生产的微波消融系统连同一次性使用的微波消融针成功获得了美国市场的准入资格，作为FDA II类监管器械开始在美国销售。03一波三折的上市历程百德医疗经历了复杂且充满挑战的上市过程。2021年6月30日，公司成功完成了9440万元人民币的C轮融资，此轮融资后估值达到了8.38亿元人民币。参与投资的机构包括中银国际投资、CVC资本以及国际精密集团等。作为融资的一部分，百德医疗与中银国际达成了业绩承诺协议，约定在2021和2022财年实现特定的盈利目标；若未能达成，则需向中银国际提供补偿。由于未能满足2021年的业绩承诺，百德医疗面临潜在的赔偿责任。然而，如果公司在2022年底之前能够成功上市，该业绩承诺将自动解除，这可能是促使百德医疗加快上市步伐的一个因素。首次尝试是在2021年9月28日向香港交易所提交了上市申请，但最终未能成行。随后在2022年4月7日再次提交申请，并计划于同年10月5日在港交所上市。但是，在预定上市日期前几天的10月3日，百德医疗宣布推迟IPO。经过一段时间的调整，2023年6月26日，百德医疗选择通过与一家特殊目的收购公司（SPAC）——ExcelFin Acquisition Corp.合并的方式在美国寻求上市机会。此次合并代表了百德医疗第三次冲击资本市场的机会。据透露，ExcelFin的赞助商Grand Fortune Capital同意从现有股东手中购买约880万美元的百德医疗债务，这可能与之前的业绩承诺相关。合并前百德医疗的股权价值为3亿美元，而合并后的预估企业价值约为3.7亿美元。原有股东持有的百德医疗股份将转换为新公司的普通股。最终，2024年10月2日，百德医疗以Baird Medical Investment Holdings Limited的身份在美国市场挂牌上市。在中国，微波消融治疗技术的应用处于世界领先地位，无论是临床实践还是设备制造方面均表现出色。根据智研咨询的数据，2022年全球热消融医疗服务市场的规模超过了120亿美元，其中微波消融占据了大约三分之一的份额，即约40亿美元。在国内市场占据领先地位的百德医疗成功赴美上市，这一举动吸引了众多海外投资者的目光，并促成了其近日股价飙升超过600%。然而，在美股SPAC上市的医疗公司整体表现欠佳的背景下，百德医疗能否维持稳定的增长态势仍存疑问。对此，我们将持续跟踪报道，关注百德医疗未来的表现及市场反应。海量资讯、精准解读，尽在新浪财经APP","news_type":1,"symbols_score_info":{"BDMD":0.9}},"isVote":1,"tweetType":1,"viewCount":1427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":392684520895008,"gmtCreate":1736915822676,"gmtModify":1736917538056,"author":{"id":"4164516241480402","authorId":"4164516241480402","name":"老虎油有优","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4164516241480402","authorIdStr":"4164516241480402"},"themes":[],"htmlText":"要是在底部进来就好了","listText":"要是在底部进来就好了","text":"要是在底部进来就好了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/392684520895008","repostId":"392476442398944","repostType":1,"repost":{"id":392476442398944,"gmtCreate":1736843474792,"gmtModify":1736848924720,"author":{"id":"3519157433193136","authorId":"3519157433193136","name":"美港股观察社","avatar":"https://static.tigerbbs.com/cfcc85fddcd77379cda6138d51be4c17","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519157433193136","authorIdStr":"3519157433193136"},"themes":[],"title":"底部爆拉近10倍，百德医疗缘何大涨？","htmlText":"从2024年12月31日开始，百德医疗开启连续上涨，截至2025年1月13日，公司股价在底部暴涨近10倍，吸引了投资者的广泛关注。这家公司有着怎样的背景，又为何被市场如此看好呢？让我们一探究竟。 国内领先的微波消融医疗器械供应商 百德医疗投资有限公司成立于 2012 年，总部位于中国苏州太仓港区。其境内运营实体为百德（苏州）医疗有限公司，专注于微波消融（MWA）医疗器械的研发、生产和销售。百德医疗的微波消融医疗器械已经在国内成功注册为第三类医疗器械，并且在2023年11月，公司子公司百德（苏州）医疗有限公司获得美国食品药品监督管理局FDA 510k 批准，其微波消融系统和一次性产品组合微波消融针在美国作为监管II类设备。根据弗若斯特沙利文的资料，按2022年微波消融针的销售收入和销售量计算，百德医疗是中国治疗甲状腺结节及乳腺肿块的微波消融医疗器械第一大供应商，而按照2022年销售收入计算，百德医疗是中国第三大微波消融医疗器械供应商。 2024 年初，百德医疗成功获得了中国证监会关于境外发行上市的备案通知，达成迈向国际资本市场的重要一步。随后在9月，公司完成了与 Excel Fin Acquisition Corp 的合并交易，并在10月2日成功在纳斯达克上市，并更名为“Baird Medical Investment Holdings Limited”，股票代码为“BDMD”。 微波消融技术市场空间大 上市后，百德医疗的股价并不理想，但是，其长期的增长前景正逐渐被市场所认知。百德医疗的产品包括微波消融治疗仪及与治疗仪配合使用微波消融针，通过向医疗机构销售相关产品获得收入。微波消融疗法是利用微波电磁场产热而使局部细胞组织坏死，其常见适应症包括甲状腺结节及甲状腺癌、乳腺结节、肝癌、肺结节及肺癌。相比开放性手术、化疗及放疗等，微波消融治疗临床效果令人满意，而费用更低，能够减轻患者","listText":"从2024年12月31日开始，百德医疗开启连续上涨，截至2025年1月13日，公司股价在底部暴涨近10倍，吸引了投资者的广泛关注。这家公司有着怎样的背景，又为何被市场如此看好呢？让我们一探究竟。 国内领先的微波消融医疗器械供应商 百德医疗投资有限公司成立于 2012 年，总部位于中国苏州太仓港区。其境内运营实体为百德（苏州）医疗有限公司，专注于微波消融（MWA）医疗器械的研发、生产和销售。百德医疗的微波消融医疗器械已经在国内成功注册为第三类医疗器械，并且在2023年11月，公司子公司百德（苏州）医疗有限公司获得美国食品药品监督管理局FDA 510k 批准，其微波消融系统和一次性产品组合微波消融针在美国作为监管II类设备。根据弗若斯特沙利文的资料，按2022年微波消融针的销售收入和销售量计算，百德医疗是中国治疗甲状腺结节及乳腺肿块的微波消融医疗器械第一大供应商，而按照2022年销售收入计算，百德医疗是中国第三大微波消融医疗器械供应商。 2024 年初，百德医疗成功获得了中国证监会关于境外发行上市的备案通知，达成迈向国际资本市场的重要一步。随后在9月，公司完成了与 Excel Fin Acquisition Corp 的合并交易，并在10月2日成功在纳斯达克上市，并更名为“Baird Medical Investment Holdings Limited”，股票代码为“BDMD”。 微波消融技术市场空间大 上市后，百德医疗的股价并不理想，但是，其长期的增长前景正逐渐被市场所认知。百德医疗的产品包括微波消融治疗仪及与治疗仪配合使用微波消融针，通过向医疗机构销售相关产品获得收入。微波消融疗法是利用微波电磁场产热而使局部细胞组织坏死，其常见适应症包括甲状腺结节及甲状腺癌、乳腺结节、肝癌、肺结节及肺癌。相比开放性手术、化疗及放疗等，微波消融治疗临床效果令人满意，而费用更低，能够减轻患者","text":"从2024年12月31日开始，百德医疗开启连续上涨，截至2025年1月13日，公司股价在底部暴涨近10倍，吸引了投资者的广泛关注。这家公司有着怎样的背景，又为何被市场如此看好呢？让我们一探究竟。 国内领先的微波消融医疗器械供应商 百德医疗投资有限公司成立于 2012 年，总部位于中国苏州太仓港区。其境内运营实体为百德（苏州）医疗有限公司，专注于微波消融（MWA）医疗器械的研发、生产和销售。百德医疗的微波消融医疗器械已经在国内成功注册为第三类医疗器械，并且在2023年11月，公司子公司百德（苏州）医疗有限公司获得美国食品药品监督管理局FDA 510k 批准，其微波消融系统和一次性产品组合微波消融针在美国作为监管II类设备。根据弗若斯特沙利文的资料，按2022年微波消融针的销售收入和销售量计算，百德医疗是中国治疗甲状腺结节及乳腺肿块的微波消融医疗器械第一大供应商，而按照2022年销售收入计算，百德医疗是中国第三大微波消融医疗器械供应商。 2024 年初，百德医疗成功获得了中国证监会关于境外发行上市的备案通知，达成迈向国际资本市场的重要一步。随后在9月，公司完成了与 Excel Fin Acquisition Corp 的合并交易，并在10月2日成功在纳斯达克上市，并更名为“Baird Medical Investment Holdings Limited”，股票代码为“BDMD”。 微波消融技术市场空间大 上市后，百德医疗的股价并不理想，但是，其长期的增长前景正逐渐被市场所认知。百德医疗的产品包括微波消融治疗仪及与治疗仪配合使用微波消融针，通过向医疗机构销售相关产品获得收入。微波消融疗法是利用微波电磁场产热而使局部细胞组织坏死，其常见适应症包括甲状腺结节及甲状腺癌、乳腺结节、肝癌、肺结节及肺癌。相比开放性手术、化疗及放疗等，微波消融治疗临床效果令人满意，而费用更低，能够减轻患者","images":[{"img":"https://static.tigerbbs.com/2df824769405b0aec3f33f4a8555e283","width":"1345","height":"698"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/392476442398944","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2055,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}